EyEnovia, Inc. Signs Material Definitive Agreement

TL;DR

EYEN just signed a big deal, details TBD.

AI Summary

On December 5, 2024, EyEnovia, Inc. entered into a Material Definitive Agreement. The filing does not specify the other party or the nature of the agreement, but it is classified as a significant event requiring immediate disclosure.

Why It Matters

This filing indicates a significant development for EyEnovia, Inc., potentially impacting its business operations, strategic direction, or financial standing.

Risk Assessment

Risk Level: medium — The lack of specific details about the agreement introduces uncertainty, making it difficult to assess the immediate impact and associated risks.

Key Players & Entities

• EyEnovia, Inc. (company) — Registrant
• December 5, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — on which registered) Common stock, $0.0001 par value EYEN The Nasdaq Stock Mar
• $0.0969 — each Share and accompanying Warrants is $0.0969 . The combined offering price for each
• $1.95 million — fering are expected to be approximately $1.95 million. The Company intends to use the net pro

Filing Documents

• tm2430479d1_8k.htm (8-K) — 39KB
• tm2430479d1_ex4-1.htm (EX-4.1) — 102KB
• tm2430479d1_ex4-2.htm (EX-4.2) — 94KB
• tm2430479d1_ex5-1.htm (EX-5.1) — 15KB
• tm2430479d1_ex10-1.htm (EX-10.1) — 171KB
• tm2430479d1_ex99-1.htm (EX-99.1) — 11KB
• tm2430479d1_ex5-1img01.jpg (GRAPHIC) — 12KB
• tm2430479d1_ex5-1img02.jpg (GRAPHIC) — 1KB
• tm2430479d1_ex99-1img01.jpg (GRAPHIC) — 7KB
• tm2430479d1_ex99-1img02.jpg (GRAPHIC) — 2KB
• 0001104659-24-126533.txt ( ) — 746KB
• eyen-20241205.xsd (EX-101.SCH) — 3KB
• eyen-20241205_lab.xml (EX-101.LAB) — 33KB
• eyen-20241205_pre.xml (EX-101.PRE) — 22KB
• tm2430479d1_8k_htm.xml (XML) — 4KB

01. Entry Into a Material Definitive

Item 1.01. Entry Into a Material Definitive Agreement. Registered Direct Offering On December 5, 2024, Eyenovia, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with an institutional investor, pursuant to which the Company agreed to sell, in a registered direct offering by the Company (the "Offering"), 11,000,000 shares (the "Shares") of common stock, par value $0.0001 per share (the "Common Stock"), pre-funded warrants to purchase up to 9,085,025 shares of Common Stock (the "Pre-Funded Warrants") and warrants to purchase up to 40,170,050 shares of Common Stock (the "Warrants") . The combined offering price for each Share and accompanying Warrants is $0.0969 . The combined offering price for each Pre-Funded Warrant and accompanying Warrants is $ 0.0968 , which is equal to the purchase price per Share in the Offering, minus $ 0.0001 . The Warrants will be exercisable upon receipt of approval of the Company's stockholders in accordance with the applicable rules and regulations of The Nasdaq Capital Market, and may be exercised for five years from the initial exercisability date at an exercise price of $0.0969 per share. The Company has agreed to hold an annual or special meeting of stockholders on or prior to the date that is 90 days following the date of issuance of the Warrants for the purpose of obtaining such approval. The exercise price and number of shares of Common Stock issuable upon exercise of the Warrants will be subject to adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Stock. The Warrants will be issued in certificated form only. A holder may not exercise any portion of such holder's Warrants to the extent that the holder would own more than 4.99% of our outstanding Common Stock immediately after exercise (unless the holder otherwise elects a limitation of 9.99%). The Pre-Funded Warrants will be immediately exercisable at an exercise price

Forward-Looking Statements

Forward-Looking Statements Except for historical information, all the statements, expectations and assumptions contained in this Current Report on Form 8-K are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements relating to the Company's future activities or other future events or conditions, including statements regarding the completion of the Offering, the intended use of net proceeds from the Offering, the Company's agreement to hold a meeting of stockholders in connection with the Warrants, and the Company's regulatory and strategic activities. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which the Company files with the SEC. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, the Company does not undertake any obligation to update any forward-looking statements.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On December 6, 2024, the Company issued a press release announcing the Offering. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Michael Rowe, Chief Executive Officer of Eyenovia, our organization, to allow us to continue to advance the development of our Gen-2 Optejet device, with the goal of registering that device in the United States in the third quarter of 2025. We are now focused on expanding the capabilities of the Gen-2 device, such that it can be consumer-filled with standard eye drops such as artificial tears that could be marketed without the need for additional clinical studies. In addition to these internal development initiatives, the Optejet is generating significant interest among potential strategic partners, and we are engaged in productive discussions with multiple parties, including our lender, Avenue Capital. I remain optimistic as we continue to work to maximize the value of the Gen-2 device and Eyenovia as a whole." The information contained in this Item 7.01, including Exhibit 99.1, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Warrant. 4.2 Form of Pre-Funded Warrant. 5.1 Opinion of Covington & Burling LLP. 10.1 Form of Securities Purchase Agreement, dated December 5, 2024. 23.1 Consent of Covington & Burling LLP (included in Exhibit 5.1). 99.1 Press Release, dated December 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYENOVIA, INC. Date: December 9, 2024 /s/ Michael Rowe Michael Rowe Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR